Roche’s investigational cancer drug divarasib reduced the risk of death by 44 per cent compared with existing treatments in a phase III trial involving patients with lung cancer.
New treatments for ALS are raising hopes among researchers. “The earlier a patient receives targeted gene therapy, the ...
In May, Vitrolife announced that Bronwyn Brophy O'Connor had decided to step down as President and CEO to take up the same ...
Medical device manufacturers will be spared duplicate certification processes to access the British market. The UK government ...
MEMBER ANNOUNCEMENT - Gruber A/S will join the Danish Pavilion at COMPAMED in Düsseldorf on 16–19 November 2026, with a focus ...
AstraZeneca’s experimental cancer treatment sone-ve delivered longer survival than analysts had expected in a phase III trial ...
Eli Lilly’s advertising campaign about obesity did not breach industry rules on advertising aimed at the general public, ...
New treatments for ALS are raising hopes among researchers. “The earlier a patient receives targeted gene therapy, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results